Oncotarget
Nanobody Inhibits Metastasis of Breast Tumor Cells to Lung in Mice
Aug 15, 2024
Zhen Li, a researcher from Tufts University, dives into groundbreaking findings on a novel nanobody that targets the V-ATPase c subunit to combat breast cancer metastasis. The conversation highlights how the nanobody disrupts acidification within tumor cells and significantly curtails their ability to invade. Intriguingly, the group demonstrates that this innovative approach also minimizes the spread of cancer cells to the lungs in mice, paving the way for future targeted cancer therapies.
02:53
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The novel nanobody targets the VAT-Pase C subunit, inhibiting breast cancer cell invasion and reducing media acidification in vitro.
- In vivo studies reveal that the nanobody injection significantly decreases the metastatic spread of breast tumor cells to the lungs.
Deep dives
Nanobody Development and Mechanism of Action
A novel nanobody targeting the extracellular epitope of the VAT-Pase C subunit has been developed, showing significant promise in inhibiting breast cancer metastasis. This ATP-dependent proton pump plays a critical role in regulating the pH of intracellular compartments and facilitating proton transport in various cell types, including cancer cells. The nanobody effectively inhibits VAT-Pase dependent acidification of the media and decreases the invasion capability of 4T1-12B breast cancer cells in vitro. By selectively inhibiting VAT-Pases in these cells, researchers have highlighted a crucial mechanism that could be pivotal in developing future cancer therapies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
